ICON Public (ICLR) Stock Forecast & Price Target

$207.51 +2.90 (+1.42%)

(As of 12/20/2024 05:31 PM ET)

ICON Public - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
0

Hold
3

Buy
10

Based on 13 Wall Street analysts who have issued ratings for ICON Public in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 3 have given a hold rating, 9 have given a buy rating, and 1 has given a strong buy rating for ICLR.

Consensus Price Target

$289.10
39.32% Upside

According to the 13 analysts' twelve-month price targets for ICON Public, the average price target is $289.10. The highest price target for ICLR is $350.00, while the lowest price target for ICLR is $225.00. The average price target represents a forecasted upside of 39.32% from the current price of $207.51.

Get the Latest News and Ratings for ICLR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ICON Public and its competitors.

ICLR Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	10 Buy rating(s)	11 Buy rating(s)	8 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$289.10	$292.45	$351.60	$291.55
Forecasted Upside	39.32% Upside	36.50% Upside	18.66% Upside	3.90% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Buy

I was wrong. Dead wrong. (Ad)

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

ICLR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ICLR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ICON Public Stock vs. The Competition

Type	ICON Public	Medical Companies	S&P 500
Consensus Rating Score	2.85	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	39.32% Upside	25,827.32% Upside	14.53% Upside
News Sentiment Rating	Neutral News See Recent ICLR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/18/2024	Truist Financial 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$295.00 ➝ $284.00	+39.48%
11/20/2024	Robert W. Baird 2 of 5 stars		Lower Target	Neutral ➝ Neutral	$249.00 ➝ $225.00	+15.03%
11/19/2024	Leerink Partners 1 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$270.00 ➝ $255.00	+34.38%
10/25/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$369.00 ➝ $285.00	+28.55%
10/25/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$330.00 ➝ $275.00	+24.47%
10/25/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$375.00 ➝ $280.00	+22.95%
Trump’s Sending THIS Crypto Higher on Purpose (Ad) Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW
10/25/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$370.00 ➝ $280.00	+22.95%
10/24/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Coldwell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
10/14/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Clark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$311.00	+5.43%
10/8/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$360.00 ➝ $350.00	+21.46%
9/18/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/31/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
4/4/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$346.00	+7.76%
12/11/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$300.00 ➝ $315.00	+15.61%
7/14/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$280.00 ➝ $300.00	+21.55%
5/1/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$245.00 ➝ $220.00	+14.17%
4/28/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$271.00 ➝ $263.00	+37.91%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 09:04 AM ET.

Should I Buy ICON Public Stock? ICLR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, December 13, 2024. Please send any questions or comments about these ICON Public pros and cons to contact@marketbeat.com.

ICON Public
Bull Case

Here are some ways that investors could benefit from investing in ICON Public Limited:

Recent increase in institutional investment, with Icon Wealth Advisors LLC raising its stake by 861.1%, indicating strong confidence in the company's future performance.
Current stock price of $214.25, which reflects a recent uptick of 0.7%, suggesting potential for short-term gains.
Despite a slight revenue decline, the company reported a solid earnings per share (EPS) of $3.35, demonstrating resilience in a challenging market environment.
Analysts maintain a consensus rating of "Moderate Buy" with a target price of $292.45, indicating potential upside for investors based on future performance expectations.
ICON Public Limited has a strong market capitalization of $17.68 billion, which provides stability and resources for growth and development in the medical research sector.

ICON Public
Bear Case

Investors should be bearish about investing in ICON Public Limited for these reasons:

The company missed analysts' consensus EPS estimates by $0.37, which may raise concerns about its ability to meet future financial targets.
Revenue for the latest quarter was down 1.2% year-over-year, indicating potential challenges in maintaining growth in a competitive market.
Several analysts have downgraded their price targets for ICON Public Limited, reflecting a cautious outlook on the stock's performance.
The company's net margin of 9.00% and return on equity of 11.91% may be viewed as lower than industry standards, suggesting less efficiency in generating profits from investments.
With a beta of 1.25, the stock is more volatile than the market, which could pose risks for investors seeking stability in their portfolios.

ICLR Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for ICON Public is $289.10, with a high forecast of $350.00 and a low forecast of $225.00.
: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ICON Public in the last twelve months. There are currently 3 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ICLR shares.
: According to analysts, ICON Public's stock has a predicted upside of 39.32% based on their 12-month stock forecasts.
: Over the previous 90 days, ICON Public's stock had 2 downgrades by analysts.
: ICON Public has been rated by research analysts at Baird R W, Barclays, Evercore ISI, JPMorgan Chase & Co., Leerink Partners, Redburn Atlantic, Robert W. Baird, TD Cowen, The Goldman Sachs Group, and Truist Financial in the past 90 days.
: Analysts like ICON Public more than other "medical" companies. The consensus rating score for ICON Public is 2.85 while the average consensus rating score for "medical" companies is 2.81. Learn more on how ICLR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

This page (NASDAQ:ICLR) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ICON Public (ICLR) Stock Forecast & Price Target